Areas of Interest - Clinical Research

COPD (chronic bronchitis and emphysema)

Respimat Tiotropium:
A placebo-controlled, 12 month clinical trial testing the efficacy of TIOTROPIUM (SPIRIVA) in an inhaler device named RESPIMAT. Chance of receiving active study medication is 66%.
PRINCIPAL INVESTIGATOR: CHRISTOPHER B. COOPER, MD
STUDY COORDINATOR: ANDREW P. RANDOLPH (310) 794-2156

Advair SCO40030:
A placebo-controlled, 3 month clinical trial testing the efficacy of the FDA approved medication, ADVAIR in patients with COPD. Chance of receiving active study medication is 66%.
PRINCIPAL INVESTIGATOR: CHRISTOPHER B. COOPER, MD
STUDY COORDINATOR: ANDREW P. RANDOLPH (310) 794-2156

Ariflo 180:
A placebo-controlled, 6 month clinical trial testing the efficacy of a drug called ARIFLO (both at rest and during exercise) in patients with COPD. Chance of receiving active study medication is 50%.
PRINCIPAL INVESTIGATOR: CHRISTOPHER B. COOPER, MD
STUDY COORDINATOR: ANDREW P. RANDOLPH (310) 794-2156

ONO 6126:
A placebo-controlled, 3 month clinical trial testing the efficacy of a drug called ONO 6126 in decreasing inflammation of the respiratory tract in patients with COPD. Chance of receiving active study medication is 66%.
PRINCIPAL INVESTIGATOR: CHRISTOPHER B. COOPER, MD
STUDY COORDINATOR: ANDREW P. RANDOLPH (310) 794-2156

Tiotropium Uplift:
A 4-year study comparing inhaled tiotroprium with placebo in people with COPD. The purpose of this study is to see whether tiotropium prevents the disease from getting worse over time.
PRINCIPAL INVESTIGATOR: DONALD TASHKIN, M.D.
STUDY COORDINATOR: IAN ZUNIGA (310) 794-9107

Roflumilast:
Effect of Roflumilast on exacerbation rate in patients with COPD.
PRINCIPAL INVESTIGATOR: DONALD TASHKIN M.D.
STUDY COORDINATOR: IAN ZUNIGA (310) 794-9107

Formoterol Fumarate:
A 12-week trial to evaluate the efficacy and safety of formoterol inhalation solution in the treatment of patients with COPD.
PRINCIPAL INVESTIGATOR: DONALD TASHKIN, M.D.
PROJECT COORDINATOR: IAN ZUNIGA, (310) 794-9107

RAR gamma:
A comparative study of the safety and tolerability of two doses of an experimental drug (RAR GAMMA) versus placebo in individuals with emphysema.
PRINCIPAL INVESTIGATOR: MICHAEL ROTH, M.D.
PROJECT COORDINATORS: JOHN DERMAND, GRACE IBRAHIM: (310) 825-3421

>>back to top